0001385508-23-000036.txt : 20230207 0001385508-23-000036.hdr.sgml : 20230207 20230207162616 ACCESSION NUMBER: 0001385508-23-000036 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230202 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230207 DATE AS OF CHANGE: 20230207 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OPIANT PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001385508 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 464744124 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38193 FILM NUMBER: 23595417 BUSINESS ADDRESS: STREET 1: 233 WILSHIRE BLVD STREET 2: SUITE 400 CITY: SANTA MONICA STATE: CA ZIP: 90401 BUSINESS PHONE: (310) 598-5410 MAIL ADDRESS: STREET 1: 233 WILSHIRE BLVD STREET 2: SUITE 400 CITY: SANTA MONICA STATE: CA ZIP: 90401 FORMER COMPANY: FORMER CONFORMED NAME: Lightlake Therapeutics Inc. DATE OF NAME CHANGE: 20091009 FORMER COMPANY: FORMER CONFORMED NAME: Madrona Ventures, Inc. DATE OF NAME CHANGE: 20070108 8-K 1 opnt-20230202.htm 8-K opnt-20230202
0001385508FALSE00013855082023-02-032023-02-030001385508dei:FormerAddressMember2023-02-032023-02-03

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 8-K
 
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  February 2, 2023
 
OPIANT PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3819346-4744124
(State or other jurisdiction of
incorporation)
(Commission File Number

(IRS Employer Identification No.)








233 Wilshire Blvd. Suite 400
Santa Monica, CA

90401
(Address of Principal Executive Offices)


(Zip Code)
(310) 598 5410
Registrant’s telephone number, including area code
233 Wilshire Blvd. Suite 400, Santa Monica, CA 90401
(Former name or former address if changed since last report,)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbolName of each exchange on which registered
Common stock, par value $0.001 per shareOPNTNasdaq Stock Market LLC
 




Item 8.01 Other Events.
On February 6, 2023, Opiant Pharmaceuticals, Inc. (“Opiant”) issued a press release announcing that, with respect to the pending acquisition of Opiant by Indivior Inc., a Delaware corporation (“Parent”) and a wholly owned subsidiary of Indivior PLC (“Indivior”) (the “Merger”), on February 2, 2023, the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired. A copy of the press release is filed as Exhibit 99.1 hereto.
On February 7, 2023, Opiant issued a press release announcing that, with respect to the Merger, on February 6, 2023, the parties received written notice from the Committee on Foreign Investments in the United States that it had determined that there were no unresolved national security concerns regarding the transaction and that it had concluded action under Section 721 of the Defense Production Act of 1950, as amended, thereby clearing the transaction contemplated by the Merger Agreement. The press release also announced that the Competition and Markets Authority in the United Kingdom elected to take no action with regard to the Merger. A copy of the press release is filed as Exhibit 99.2 hereto.

The parties have received all necessary regulatory clearances required pursuant to the previously announced Agreement and Plan of Merger, dated as of November 13, 2022 (the “Merger Agreement”), by and among Opiant, Parent and Olive Acquisition Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”). The Merger is expected to close in the first quarter of 2023, subject to the approval of Opiant’s stockholders and other customary closing conditions.
Cautionary Statement Regarding Forward-Looking Statements
This document contains “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements discuss matters that are not historical facts. Because they discuss future events or conditions, forward-looking statements may include words such as “anticipate,” “believe,” “estimate,” “intend,” “could,” “should,” “would,” “may,” “seek,” “plan,” “might,” “will,” “expect,” “predict,” “project,” “forecast,” “potential,” “continue”, negatives thereof or similar expressions. Forward-looking statements speak only as of the date they are made, are based on various underlying assumptions and current expectations about the future and are not guarantees. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, level of activity, performance or achievement to be materially different from the results of operations or plans expressed or implied by such forward-looking statements.
Opiant cannot predict all of the risks and uncertainties. Accordingly, such information should not be regarded as representations that the results or conditions described in such statements or that Opiant’s objectives and plans will be achieved and we do not assume any responsibility for the accuracy or completeness of any of these forward-looking statements. These forward-looking statements are found at various places throughout this document and include information concerning possible or assumed future results of Opiant’s operations, the expected closing date of the Merger, the achievement and value of contingent value rights in connection with the Merger; business strategies; future cash flows; financing plans; plans and objectives of management, any other statements regarding future cash needs, future operations, business plans and future financial results, and any other statements that are not historical facts. Actual results


and outcomes may differ materially from what is contained in such forward-looking statements as a result of various factors, including, without limitation: (1) the inability to consummate the transaction within the anticipated time period, or at all, due to any reason, including the failure to obtain stockholder approval to adopt the Merger Agreement or the failure to satisfy the remaining conditions to the consummation of the Merger; (2) the risk that the Merger Agreement may be terminated in circumstances requiring Opiant to pay a termination fee; (3) the risk that the Merger disrupts Opiant’s current business and financing plans and operations or diverts management’s attention from its ongoing business; (4) the effect of the announcement of the Merger on Opiant’s ability to retain and hire key personnel and maintain relationships with its suppliers and others with whom it does business; (5) the effect of the announcement of the Merger on Opiant’s operating results and business generally; (6) the amount of costs, fees and expenses related to the Merger; (7) the risk that Opiant’s stock price may decline significantly if the Merger is not consummated; (8) the nature, cost and outcome of any litigation and other legal proceedings, including any such proceedings related to the Merger and instituted against Opiant and others; (9) other factors that could affect Opiant’s business such as, without limitation, our ability to obtain and maintain regulatory approvals for our products; results of clinical studies; technological breakthroughs in reversing opioid overdoses and treating patients; and delays or unplanned expenditures in product development, clinical testing or manufacturing; and (10) other risks to consummation of the Merger, including the risk that the Merger will not be consummated within the expected time period or at all.
In addition, please refer to the documents that Opiant files with the U.S. Securities and Exchange Commission (the “SEC”) on Forms 10-K, 10-Q and 8-K. These filings identify and address other important factors that could cause Opiant’s operational and other results to differ materially from those contained in the forward-looking statements set forth in this document. You are cautioned to not place undue reliance on forward-looking statements, which speak only as of the date of this document. Except as required by law, Opiant is not under any duty to update any of the information in this document.
Important Additional Information and Where to Find It
This communication is being made in respect of the Merger involving Opiant, Parent and Merger Sub. A meeting of the stockholders of Opiant will be held on March 1, 2023 to seek stockholder approval in connection with the Merger. In connection with the Merger, on January 4, 2023, Opiant filed with the SEC a definitive proxy statement and other relevant documents seeking the approval from stockholders of Opiant for the respective transaction-related proposals. This document is not a substitute for the proxy statement or any other document that Opiant may file with the SEC. INVESTORS AND STOCKHOLDERS OF OPIANT ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS AND ANY OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC IN CONNECTION WITH THE MERGER OR INCORPORATED BY REFERENCE IN THE PROXY STATEMENT, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT OPIANT AND THE MERGER. Investors may obtain a free copy of these materials (when they are available) and other documents filed by Opiant with the SEC at the SEC’s website at www.sec.gov.
Opiant and certain of its directors, executive officers and other members of management and employees may be deemed to be participants in soliciting proxies from its stockholders in connection with the Merger. Information regarding the persons who may, under the rules of the SEC, be considered to be participants in the solicitation of Opiant’s stockholders in connection


with the Merger will be set forth in Opiant’s definitive proxy statement for its stockholder meeting at which the Merger will be submitted for approval by Opiant’s stockholders and the Annual Report on Form 10-K for the fiscal year ended December 31, 2021. You may also find additional information about Opiant’s directors and executive officers in Opiant’s definitive proxy statement for its 2022 annual meeting of stockholders, which was filed with the SEC on April 18, 2022 and in subsequently filed Current Reports on Form 8-K and Quarterly Reports on Form 10-Q.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.     Description






SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
  OPIANT PHARMACEUTICALS, INC.
  
    
Date: February 7, 2023 By:/s/ David O'Toole
   David O’Toole
   Chief Financial Officer
 


 EX-99.1 2 opntpressrelease_hsrapprov.htm EX-99.1 Document
Exhibit 99.1
Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC


SANTA MONICA, Calif., February 6, 2023 – Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced today the expiration of the waiting period under the United States (U.S.) Hart-Scott-Rodino Act of 1976, as amended (HSR Act), with respect to the previously announced agreement for Opiant to be acquired by Indivior PLC (LSE: INDV).
The waiting period expired on February 2, 2023, without any action taken by the Federal Trade Commission (FTC). The HSR Act is a key U.S. antitrust statute that enables the FTC and Department of Justice (DOJ) to review proposed merger transactions by requiring the parties to observe a waiting period before closing their transaction.
Completion of the transaction is subject to the satisfaction of the remaining customary closing conditions, including approval by Opiant stockholders and the receipt of remaining applicable regulatory approvals. Indivior and Opiant continue to anticipate completing the merger agreement in the first quarter of 2023.

Reminder to Opiant Stockholders

Stockholders are reminded:

•Opiant has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) and established January 4, 2023, as the record date for voting in connection with the merger agreement (Agreement). The proxy statement is available at www.sec.gov.
•Under the terms of the Agreement, Indivior will acquire all the outstanding shares of Opiant for upfront consideration of $20.00 per share in cash at closing, plus contingent value rights (CVRs) representing potential additional payments of up to $8.00 per share. 
•A special meeting of Opiant’s stockholders to approve the acquisition will be held on March 1, 2023, at 9:00 AM, Pacific Time, and can be accessed by visiting http://web.lumiagm.com/254970090. The meeting will be held in a virtual format only and         will be accessible through the Internet in order to permit our stockholders to participate from any geographic location with Internet connectivity.
•All stockholders of Opiant are strongly encouraged to read the definitive proxy statement carefully and in its entirety before voting, and to vote as soon as possible in advance of the special meeting.
•The Opiant Board of Directors unanimously recommends that stockholders vote “FOR” the approval and adoption of the Agreement and the approval of the acquisition.

For More Information and How to Vote Shares to the Offer
Stockholders who hold Opiant Shares through a broker or intermediary should promptly contact their broker directly and provide their instructions to vote their shares.
Opiant has engaged D.F. King & Co., Inc (D.F. King) as its proxy solicitor in connection with the voting of shares and the special meeting. Stockholders who need additional copies of proxy materials, to obtain proxy cards or have questions regarding the proposal to be presented at the special meeting are encouraged to reach out to D.F. King by calling 212-269-5550. To obtain timely delivery of documents, stockholders must request voting-related materials no later than February 22, 2023.


Exhibit 99.1

About Opiant Pharmaceuticals, Inc. 

Opiant Pharmaceuticals, Inc., is building a leading franchise of new medicines to combat addictions and drug overdose. For more information visit: www.opiant.com.
Additional Information About the Acquisition and Where to Find It
This communication is being made in respect of the proposed merger involving Opiant Pharmaceuticals, Inc. (“Opiant”), Indivior Inc. (“Indivior”) and Olive Acquisition Subsidiary. A meeting of the stockholders of Opiant will be held on March 1, 2023 to seek stockholder approval in connection with the proposed merger. In connection with the proposed merger, Opiant filed with the U.S. Securities and Exchange Commission (the “SEC”) a definitive proxy statement and other relevant documents seeking the approval from stockholders of Opiant for the respective transaction-related proposals. Beginning on January 6, 2023, Opiant mailed the Definitive Proxy Statement to the stockholders of Opiant. INVESTORS AND STOCKHOLDERS OF OPIANT ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS AND ANY OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED MERGER OR INCORPORATED BY REFERENCE IN THE PROXY STATEMENT, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT OPIANT AND THE PROPOSED MERGER. Investors may obtain a free copy of these materials (when they are available) and other documents filed by Opiant with the SEC at the SEC’s website at www.sec.gov.
Participants in the Solicitation
Opiant and certain of its directors, executive officers and other members of management and employees may be deemed to be participants in soliciting proxies from its stockholders in connection with the proposed merger. Information regarding the persons who may, under the rules of the SEC, be considered to be participants in the solicitation of Opiant’s stockholders in connection with the proposed merger is set forth in Opiant’s definitive proxy statement for its stockholder meeting at which the proposed merger will be submitted for approval by Opiant’s stockholders and the Annual Report on Form 10-K for the fiscal year ended December 31, 2021. You may also find additional information about Opiant’s directors and executive officers in Opiant’s Definitive Proxy Statement for its 2022 annual meeting of stockholders, which was filed with the SEC on April 18, 2022 and in subsequently filed Current Reports on Form 8-K and Quarterly Reports on Form 10-Q.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements,” within the meaning of Section 27A of the Securities, Act of 1993, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements discuss matters that are not historical facts. Because they discuss future events or conditions, forward-looking statements may include words such as “anticipate,” “believe,” “estimate,” “intend,” “could,” “should,” “would,” “may,” “seek,” “plan,” “might,” “will,” “expect,” “predict,” “project,” “forecast,” “potential,” “continue”, negatives thereof or similar expressions. Forward-looking statements speak only as of the date they are made, are based on various underlying assumptions and current expectations about the future and are not guarantees. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, level of activity, performance or achievement to be materially different from the results of operations or plans expressed or implied by such forward-looking statements.


Opiant cannot predict all of the risks and uncertainties. Accordingly, such information should not be regarded as representations that the results or conditions described in such statements or that Opiant’s objectives and plans will be achieved and we do not assume any responsibility for the accuracy or completeness of any of these forward-looking statements. These forward-looking statements are found at various places throughout this document and include information concerning possible or assumed future results of Opiant’s operations, the achievement and value of contingent value rights in connection with the proposed merger; business strategies; future cash flows; financing plans; plans and objectives of management, any other statements regarding future cash needs, future operations, business plans and future financial results, and any other statements that are not historical facts. Actual results and outcomes may differ materially from what is contained in such forward-looking statements as a result of various factors, including, without limitation: (1) the inability to consummate the transaction within the anticipated time period, or at all, due to any reason, including the failure to obtain stockholder approval to adopt the Merger Agreement, the failure to obtain required regulatory approvals or the failure to satisfy the other conditions to the consummation of the proposed merger; (2) the risk that the Merger Agreement may be terminated in circumstances requiring Opiant to pay a termination fee; (3) the risk that the proposed merger disrupts Opiant’s current business and financing plans and operations or diverts management’s attention from its ongoing business; (4) the effect of the announcement of the proposed merger on Opiant’s ability to retain and hire key personnel and maintain relationships with its suppliers and others with whom it does business; (5) the effect of the announcement of the proposed merger on Opiant’s operating results and business generally; (6) the amount of costs, fees and expenses related to the proposed merger; (7) the risk that Opiant’s stock price may decline significantly if the proposed merger is not consummated; (8) the nature, cost and outcome of any litigation and other legal proceedings, including any such proceedings related to the proposed merger and instituted against Opiant and others; (9) other factors that could affect Opiant’s business such as, without limitation, our ability to obtain and maintain regulatory approvals for our products; results of clinical studies; technological breakthroughs in reversing opioid overdoses and treating patients; and delays or unplanned expenditures in product development, clinical testing or manufacturing; and (10) other risks to consummation of the proposed merger, including the risk that the proposed merger will not be consummated within the expected time period or at all.
In addition, please refer to the documents that Opiant files with the SEC on Forms 10-K, 10-Q and 8-K. These filings identify and address other important factors that could cause Opiant’s operational and other results to differ materially from those contained in the forward-looking statements set forth in this document. You are cautioned to not place undue reliance on forward-looking statements, which speak only as of the date of this document. Except as required by law, Opiant is not under any duty to update any of the information in this document.

For Media and Investor Inquiries:
Ben Atkins, Opiant
(310) 598-5410
batkins@opiant.com



 EX-99.2 3 opntpressrelease_cfiusappr.htm EX-99.2 Document
Exhibit 99.2
Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC

•CFIUS clearance represents the final required regulatory approval to complete the proposed merger

•Completion remains subject to the approval of Opiant stockholders; a special stockholder meeting to approve the acquisition will be held on March 1, 2023

•Indivior and Opiant continue to anticipate completing the proposed merger in the first quarter of 2023.

SANTA MONICA, Calif., February 7, 2023 – Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced today that the Committee on Foreign Investment in the United States (“CFIUS”) approved the previously announced Merger Agreement (the “Agreement”) for Opiant to be acquired by Indivior PLC (LSE: INDV).

Following the expiration of the waiting period under the U.S. Hart-Scott-Rodino Act of 1976, as amended (HSR Act), which Opiant previously announced, on February 6, 2023, the parties received written notice from CFIUS that it had determined that there were no unresolved national security concerns regarding the transaction and that it had concluded action under Section 721 of the Defense Production Act of 1950, as amended, thereby clearing the transaction contemplated by the Agreement. Additionally, the Competition and Markets Authority in the United Kingdom has elected to take no action with regard to the proposed merger.

The proposed merger remains subject to approval by Opiant stockholders. A special meeting of Opiant’s stockholders to approve the Agreement will be held on March 1, 2023. Indivior and Opiant continue to anticipate completing the Agreement in the first quarter of 2023.

Reminder to Opiant Stockholders

Stockholders are reminded:

•Opiant has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) and established January 4, 2023, as the record date for voting in connection with the Agreement. The proxy statement is available at www.sec.gov.
•Under the terms of the Agreement, Indivior will acquire all the outstanding shares of Opiant for upfront consideration of $20.00 per share in cash at closing, plus contingent value rights (CVRs) representing potential additional payments of up to $8.00 per share. 
•A special meeting of Opiant’s stockholders to approve the acquisition will be held on March 1, 2023, at 9:00 AM, Pacific Time, and can be accessed by visiting http://web.lumiagm.com/254970090. The meeting will be held in a virtual format only and will be accessible through the Internet in order to permit our stockholders to participate from any geographic location with Internet connectivity.
•All stockholders of Opiant are strongly encouraged to read the definitive proxy statement carefully and in its entirety before voting, and to vote as soon as possible in advance of the special meeting.
•The Opiant Board of Directors unanimously recommends that stockholders vote “FOR” the approval and adoption of the Agreement and the approval of the acquisition.






Exhibit 99.2
For More Information and How to Vote Shares to the Offer

Stockholders who hold Opiant Shares through a broker or intermediary should promptly contact their broker directly and provide their instructions to vote their shares.

Opiant has engaged D.F. King & Co., Inc (D.F. King) as its proxy solicitor in connection with the voting of shares and the special meeting. Stockholders who need additional copies of proxy materials, to obtain proxy cards or have questions regarding the proposal to be presented at the special meeting are encouraged to reach out to D.F. King by calling 212-269-5550. To obtain timely delivery of documents, stockholders must request voting-related materials no later than February 22, 2023.

About Opiant Pharmaceuticals, Inc. 

Opiant Pharmaceuticals, Inc., is building a leading franchise of new medicines to combat addictions and drug overdose. For more information visit: www.opiant.com.
Additional Information About the Acquisition and Where to Find It
This communication is being made in respect of the proposed merger involving Opiant Pharmaceuticals, Inc. (“Opiant”), Indivior Inc. (“Indivior”) and Olive Acquisition Subsidiary. A meeting of the stockholders of Opiant will be held on March 1, 2023 to seek stockholder approval in connection with the proposed merger. In connection with the proposed merger, Opiant filed with the U.S. Securities and Exchange Commission (the “SEC”) a definitive proxy statement and other relevant documents seeking the approval from stockholders of Opiant for the respective transaction-related proposals. Beginning on January 6, 2023, Opiant mailed the Definitive Proxy Statement to the stockholders of Opiant. INVESTORS AND STOCKHOLDERS OF OPIANT ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS AND ANY OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED MERGER OR INCORPORATED BY REFERENCE IN THE PROXY STATEMENT, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT OPIANT AND THE PROPOSED MERGER. Investors may obtain a free copy of these materials (when they are available) and other documents filed by Opiant with the SEC at the SEC’s website at www.sec.gov.
Participants in the Solicitation
Opiant and certain of its directors, executive officers and other members of management and employees may be deemed to be participants in soliciting proxies from its stockholders in connection with the proposed merger. Information regarding the persons who may, under the rules of the SEC, be considered to be participants in the solicitation of Opiant’s stockholders in connection with the proposed merger is set forth in Opiant’s definitive proxy statement for its stockholder meeting at which the proposed merger will be submitted for approval by Opiant’s stockholders and the Annual Report on Form 10-K for the fiscal year ended December 31, 2021. You may also find additional information about Opiant’s directors and executive officers in Opiant’s Definitive Proxy Statement for its 2022 annual meeting of stockholders, which was filed with the SEC on April 18, 2022 and in subsequently filed Current Reports on Form 8-K and Quarterly Reports on Form 10-Q.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements,” within the meaning of Section 27A of the Securities, Act of 1993, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements discuss matters that are not historical facts. Because they discuss future events or conditions, forward-looking


statements may include words such as “anticipate,” “believe,” “estimate,” “intend,” “could,” “should,” “would,” “may,” “seek,” “plan,” “might,” “will,” “expect,” “predict,” “project,” “forecast,” “potential,” “continue”, negatives thereof or similar expressions. Forward-looking statements speak only as of the date they are made, are based on various underlying assumptions and current expectations about the future and are not guarantees. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, level of activity, performance or achievement to be materially different from the results of operations or plans expressed or implied by such forward-looking statements.
Opiant cannot predict all of the risks and uncertainties. Accordingly, such information should not be regarded as representations that the results or conditions described in such statements or that Opiant’s objectives and plans will be achieved and we do not assume any responsibility for the accuracy or completeness of any of these forward-looking statements. These forward-looking statements are found at various places throughout this document and include information concerning possible or assumed future results of Opiant’s operations, the achievement and value of contingent value rights in connection with the proposed merger; business strategies; future cash flows; financing plans; plans and objectives of management, any other statements regarding future cash needs, future operations, business plans and future financial results, and any other statements that are not historical facts. Actual results and outcomes may differ materially from what is contained in such forward-looking statements as a result of various factors, including, without limitation: (1) the inability to consummate the transaction within the anticipated time period, or at all, due to any reason, including the failure to obtain stockholder approval to adopt the Merger Agreement, the failure to obtain required regulatory approvals or the failure to satisfy the other conditions to the consummation of the proposed merger; (2) the risk that the Merger Agreement may be terminated in circumstances requiring Opiant to pay a termination fee; (3) the risk that the proposed merger disrupts Opiant’s current business and financing plans and operations or diverts management’s attention from its ongoing business; (4) the effect of the announcement of the proposed merger on Opiant’s ability to retain and hire key personnel and maintain relationships with its suppliers and others with whom it does business; (5) the effect of the announcement of the proposed merger on Opiant’s operating results and business generally; (6) the amount of costs, fees and expenses related to the proposed merger; (7) the risk that Opiant’s stock price may decline significantly if the proposed merger is not consummated; (8) the nature, cost and outcome of any litigation and other legal proceedings, including any such proceedings related to the proposed merger and instituted against Opiant and others; (9) other factors that could affect Opiant’s business such as, without limitation, our ability to obtain and maintain regulatory approvals for our products; results of clinical studies; technological breakthroughs in reversing opioid overdoses and treating patients; and delays or unplanned expenditures in product development, clinical testing or manufacturing; and (10) other risks to consummation of the proposed merger, including the risk that the proposed merger will not be consummated within the expected time period or at all.
In addition, please refer to the documents that Opiant files with the SEC on Forms 10-K, 10-Q and 8-K. These filings identify and address other important factors that could cause Opiant’s operational and other results to differ materially from those contained in the forward-looking statements set forth in this document. You are cautioned to not place undue reliance on forward-looking statements, which speak only as of the date of this document. Except as required by law, Opiant is not under any duty to update any of the information in this document.

For Media and Investor Inquiries:
Ben Atkins, Opiant
(310) 598-5410
batkins@opiant.com



 EX-101.SCH 4 opnt-20230202.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 opnt-20230202_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 opnt-20230202_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Soliciting Material Soliciting Material Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Address Type [Domain] Address Type [Domain] City Area Code City Area Code Document Information [Line Items] Document Information [Line Items] Title of 12(b) Security Title of 12(b) Security Amendment Flag Amendment Flag Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Document Period End Date Document Period End Date Entity Addresses, Address Type [Axis] Entity Addresses, Address Type [Axis] Entity Tax Identification Number Entity Tax Identification Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, City or Town Entity Address, City or Town Former Address Former Address [Member] Local Phone Number Local Phone Number Written Communications Written Communications Cover [Abstract] Document Type Document Type Document Information [Table] Document Information [Table] Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 7 opnt-20230202_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Feb. 03, 2023
Document Information [Line Items]  
Document Type 8-K
Document Period End Date Feb. 02, 2023
Entity Registrant Name OPIANT PHARMACEUTICALS, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-38193
Entity Tax Identification Number 46-4744124
Entity Address, Address Line One 233 Wilshire Blvd
Entity Address, Address Line Two Suite 400
Entity Address, City or Town Santa Monica
Entity Address, State or Province CA
Entity Address, Postal Zip Code 90401
City Area Code 310
Local Phone Number 598 5410
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Title of 12(b) Security Common stock, par value $0.001 per share
Trading Symbol OPNT
Security Exchange Name NASDAQ
Entity Central Index Key 0001385508
Amendment Flag false
Former Address  
Document Information [Line Items]  
Entity Address, Address Line One 233 Wilshire Blvd
Entity Address, Address Line Two Suite 400
Entity Address, City or Town Santa Monica
Entity Address, State or Province CA
Entity Address, Postal Zip Code 90401
XML 9 opnt-20230202_htm.xml IDEA: XBRL DOCUMENT 0001385508 2023-02-03 2023-02-03 0001385508 dei:FormerAddressMember 2023-02-03 2023-02-03 0001385508 false 8-K 2023-02-02 OPIANT PHARMACEUTICALS, INC. DE 001-38193 46-4744124 233 Wilshire Blvd Suite 400 Santa Monica CA 90401 310 598 5410 233 Wilshire Blvd Suite 400 Santa Monica CA 90401 false false false false false Common stock, par value $0.001 per share OPNT NASDAQ EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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

#1U:JQ"(6,P$ "(" / " ><0 !X;"]W;W)K8F]O M:RYX;6Q02P$"% ,4 " !'@T=6)!Z;HJT #X 0 &@ M@ %'$@ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " !' M@T=699!YDAD! #/ P $P @ $L$P 6T-O;G1E;G1?5'EP =97-=+GAM;%!+!08 "0 ) #X" !V% ! end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 2 23 1 false 1 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.opiant.com/role/Cover Cover Cover 1 false false All Reports Book All Reports opnt-20230202.htm opnt-20230202.xsd opnt-20230202_def.xml opnt-20230202_lab.xml opnt-20230202_pre.xml opntpressrelease_cfiusappr.htm opntpressrelease_hsrapprov.htm http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "opnt-20230202.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 28 }, "contextCount": 2, "dts": { "definitionLink": { "local": [ "opnt-20230202_def.xml" ] }, "inline": { "local": [ "opnt-20230202.htm" ] }, "labelLink": { "local": [ "opnt-20230202_lab.xml" ] }, "presentationLink": { "local": [ "opnt-20230202_pre.xml" ] }, "schema": { "local": [ "opnt-20230202.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 1, "nsprefix": "opnt", "nsuri": "http://www.opiant.com/20230202", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "opnt-20230202.htm", "contextRef": "ieba2ed1b16db4aca9c5f1f2429db7c10_D20230203-20230203", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://www.opiant.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "opnt-20230202.htm", "contextRef": "ieba2ed1b16db4aca9c5f1f2429db7c10_D20230203-20230203", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 1, "tag": { "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.", "label": "Address Type [Domain]", "terseLabel": "Address Type [Domain]" } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.opiant.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.opiant.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.opiant.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.opiant.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.opiant.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.opiant.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.opiant.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.opiant.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.opiant.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.opiant.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.opiant.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.opiant.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]", "terseLabel": "Entity Addresses, Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.opiant.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.opiant.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.opiant.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.opiant.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.opiant.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.opiant.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.opiant.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_FormerAddressMember": { "auth_ref": [ "r6", "r7" ], "lang": { "en-us": { "role": { "documentation": "Former address for entity", "label": "Former Address [Member]", "terseLabel": "Former Address" } } }, "localname": "FormerAddressMember", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.opiant.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.opiant.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.opiant.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.opiant.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.opiant.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.opiant.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.opiant.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.opiant.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.opiant.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Form 10-Q", "Number": "249", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Form 8-K", "Number": "249", "Publisher": "SEC", "Section": "308", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001385508-23-000036-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001385508-23-000036-xbrl.zip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